Sign in
Active, not recruitingPhase 3

Continued access to HIV treatment for people from earlier ViiV studies

Gives continued HIV treatment to adults who benefited from earlier ViiV studies.

Key facts

Who runs it
Viiv Healthcare UK Limited
Where
Bucharest, RomaniaSee the site
Registry title
A continued access study for ParticipAnts Transitioning from ViiV Healthcare-sponsored or ViiV Healthcare-collaborative parent studies for HIV treatment (PATH) Appendix: BRIGHTE
Status
Active, not recruiting
Phase
Phase 3
People taking part
5 people, planned
Started
5 Nov 2026
Expected to end
31 Dec 2030
Type of study
Interventional
Record updated
21 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people who took part in an earlier ViiV Healthcare HIV treatment study (BRIGHTE) and are still benefiting from that treatment. It lets them keep getting it.

Age
18 years or older
Sex
All sexes can join
Earlier treatment
Must have finished the treatment period of the earlier ViiV Healthcare study and still be benefiting from that treatment, as confirmed by the investigator.

Main reasons for not taking part

  • Anyone who met the earlier study's stopping or withdrawal criteria cannot join.
  • Anyone the investigator or sponsor decides cannot join for any reason.

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Investigator confirmation of the participant's continued clinical benefit from the parent study intervention and the participant’s completion of the protocol-defined treatment period in the parent study. The Investigator should ensure that the participant is still eligible for the parent study (i.e., have not met parent study discontinuation/withdrawal criteria)
  • Participants or LAR who are willing and able to comply with all scheduled visits, treatment plan, and other study procedures as outlined in the applicable appendix and determined by the Investigator
  • Participant or LAR is able and willing to provide signed informed consent as described in Protocol, which includes compliance with the requirements and restrictions listed in the consent form and this protocol. Where applicable, participants must provide written assent

Who cannot take part

  • Participants are excluded from participating in this study if the following criterion applies: Any reason that, in the opinion of the Investigator or Sponsor, precludes the participant’s inclusion in the study

Where in Romania

  • Institutul National de Boli Infectioase "Prof.Dr. Matei Bals"Bucharest, RomaniaNo longer taking part

About the trial

What the trial wants to find out

To provide continued access to study interventions for participants who were enrolled and treated in ViiV Healthcare-sponsored or ViiV Healthcare-collaborative parent studies, and who, at the time of transition to this study, continue to experience clinical benefit from this treatment, and to describe the continued use and safety of the study intervention.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 3b, open-label, multicenter, continued access study for participants transitioning from ViiV  Healthcare‑sponsored or ViiV  Healthcare‑collaborative parent studies for HIV treatment Appendix : Management of Participants from Parent Study BRIGHTE
Plain-language title
Continued access to HIV treatment for people from earlier ViiV studiesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
21 October 2026